BVS
$8.99
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular an...
Recent News
Bioventus Q4 Earnings Call Highlights
Bioventus (NASDAQ:BVS) executives told investors the company closed 2025 with what leadership described as a “solid quarter” and a “pivotal year,” highlighting stronger organic growth, higher profitability, and record quarterly operating cash flow while laying out a 2026 plan to step up investment i
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ...
Bioventus Inc (BVS) reports a robust quarter with 10% organic revenue growth, expanded EBITDA margins, and strategic advancements in growth drivers like PNS and PRP.
Bioventus Inc. Q4 2025 Earnings Call Summary
Moby summary of Bioventus Inc.'s Q4 2025 earnings call
Bioventus (BVS) Q4 2025 Earnings Call Transcript
Rob will begin his remarks with an update on our business, review our performance against our 2025 priorities, and lay out our 2026 objectives. Then Mark will review the fourth quarter results and discuss our 2026 financial guidance. Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the SEC, including Item 1A, Risk Factors, of the company's Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in the company's other filings made with the SEC.
Bioventus: Q4 Earnings Snapshot
The Durham, North Carolina-based company said it had profit of 21 cents per share. Earnings, adjusted for non-recurring costs, were 24 cents per share. The company posted revenue of $157.9 million in the period.